What's Happening?
KORU Medical Systems, a medical technology company, announced a 27% increase in net revenues for the third quarter of 2025, totaling $10.4 million compared to $8.2 million in the previous year. The company attributed
this growth to its core business, which saw a 30% increase in net revenues. KORU also announced two new collaborations in Pharma Services and Clinical Trials, aiming to expand its reach to new patient populations. Despite a net loss of $0.8 million, the company reported a positive adjusted EBITDA of $0.09 million, marking a 121% improvement over the prior year. KORU raised its full-year revenue guidance to $40.5 - $41.0 million, representing a 20% - 22% year-over-year growth.
Why It's Important?
The financial growth and strategic collaborations announced by KORU Medical Systems highlight the company's expanding influence in the medical technology sector. The increase in revenue and positive adjusted EBITDA indicate strong market demand for KORU's subcutaneous infusion solutions. The raised revenue guidance suggests confidence in continued growth, which could attract more investors and partnerships. This development is significant for stakeholders in the healthcare industry, as it reflects a growing trend towards innovative patient-centric solutions and could influence market dynamics and competition.
What's Next?
KORU Medical Systems plans to focus on accelerating revenue growth, advancing its innovation pipeline, and expanding its international footprint. The company aims to form new pharmaceutical collaborations to utilize its Freedom system globally. KORU's strategic goals include improving gross margins and maintaining positive cash flow from operations. The company will host a conference call to discuss these results and provide a corporate update, indicating ongoing transparency and engagement with investors.
